Oxford, UK – 11 October 2016. OGT, The Molecular Genetics Company, has today announced a significant expansion of its existing catalog of CytoCell® Hematology probes for fluorescence in situ hybridization (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes. These additions have been introduced due to an ongoing commitment to use customer input as a major driver for the rapid development of the latest research-relevant probes. The 14 newly launched probes are:
The new cost-effective and quality-assured probes are optimized for use on common sample types and are sold as pre-mixed, easy-to-use formulations to minimize experimental errors. The importance of researchers’ input in today’s announcement demonstrates the ongoing success of OGT’s myProbes® service, which enables scientists to order custom-made probes for virtually any sequence in the human genome. All probes are produced under GMP/GLP guidelines using the CytoCell BAC-2-FISH™ process, combining high-intensity signals with low levels of background fluorescence and providing maximum confidence in results.
As the longest-standing FISH probe manufacturer in the world, 2016 marks 25 years of CytoCell expertise and customer service in the development and production of FISH products. “myProbes gives us the opportunity to get continuous input from our customers,” explains Faidra Partheniou, Hematology Product Manager at OGT, “it truly helps us to respond quickly to changes in customer demand and it helps researchers by providing a first port of call for rapid development of new probes. These latest additions to our CytoCell portfolio are testament to this.”
OGT also offers the opportunity to evaluate the accurate, user-friendly FISH probes in customer’s own labs free of charge by simply requesting up to four free probes from their extensive range.
The new additions to the CytoCell hematology probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.
Read
Plasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.
Read
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read
Visit International site
Visit USA site
International
